Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biomea Fusion, Inc.BMEA · Entity 6606 | Director | September 17, 2021 | September 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biomea Fusion, Inc.
Report date September 17, 2021 · Filed September 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,400,000 |
Reported balance
After 2021-09-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-09-17 · Purchase · Acquired 34,658 · Balance 4,400,000 F1: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and an affiliate of A2A Pharmaceuticals Inc. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and an affiliate of A2A Pharmaceuticals Inc. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2021 Filed Sep 21, 2021 20:05 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | PurchaseCommon Stock | 34,658 | $10.96 | $379,851.68 |
DisclosureSEC source: 0000899243-21-036767 · doc4.xml · nonDerivative · entry 1 Stergiopoulos Sotirios · CIK 0001856641 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,400,000 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held directly by A2A Pharmaceuticals Inc. Sotirios Stergiopoulos is a member of the Issuer's Board of Directors and an affiliate of A2A Pharmaceuticals Inc. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:47 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 28,911 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-016299 · doc4.xml · derivative · entry 1 Stergiopoulos Sotirios · CIK 0001856641 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,911 Underlying: Common Stock · 28,911 shares Expires 2031-04-14 F1 · derivative.exercise_date: The shares underlying the stock option vest in equal monthly installments over a three year period beginning on April 20, 2021, so that all shares shall have vested on April 20, 2024, subject to the Reporting Person continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.